CPT and ICD-10 Codes for PSA Testing in Testosterone Therapy
For a total PSA test, use CPT code 84153; for free PSA, use CPT code 84154. The appropriate ICD-10-CM diagnosis code is E29.1 (hypogonadism) to justify ordering PSA monitoring in a patient on testosterone therapy.
CPT Codes for PSA Testing
Total PSA
- CPT 84153: Total prostate-specific antigen (PSA) assay
- This is the standard code for measuring total serum PSA levels
- Used for both screening and monitoring purposes
Free PSA (if ordered)
- CPT 84154: Free PSA assay
- Typically ordered when total PSA is elevated (usually between 4-10 ng/mL) to improve specificity
- Helps differentiate benign prostatic conditions from prostate cancer
- Not routinely needed for standard testosterone therapy monitoring unless total PSA is concerning
ICD-10-CM Diagnosis Code
E29.1 (Testicular hypogonadism) is the primary diagnosis code that justifies PSA monitoring in this clinical context:
- This code covers male hypogonadism requiring testosterone replacement therapy
- Provides medical necessity for PSA monitoring as part of testosterone therapy surveillance
- Alternative codes if applicable: E29.8 (Other testicular dysfunction) or E29.9 (Testicular dysfunction, unspecified)
Clinical Context and Monitoring Requirements
The Endocrine Society guidelines 1 establish clear PSA monitoring protocols for men on testosterone therapy:
Baseline Requirements
- Check PSA before initiating testosterone treatment
- Perform digital rectal examination at baseline
- Establish baseline PSA for comparison during treatment
Follow-up Monitoring Schedule
- First follow-up: 3-12 months after starting testosterone
- Subsequent monitoring: Annually thereafter for men aged 55-69 years, or men aged 40-69 years at increased prostate cancer risk who choose prostate monitoring 1
Critical Action Thresholds
The guidelines 1 specify when to obtain urological consultation:
- PSA increase >1.4 ng/mL within 12 months of starting testosterone
- Confirmed PSA >4.0 ng/mL at any time
- Detection of prostatic abnormality on digital rectal examination
- Substantial worsening of lower urinary tract symptoms
Important Clinical Considerations
Expected PSA Changes on Testosterone
Research demonstrates that testosterone therapy causes modest PSA increases 2:
- Mean PSA increase of approximately 0.47 ng/mL at 12 months
- 5% of men experience increases ≥1.7 ng/mL
- 2.5% of men experience increases ≥3.4 ng/mL
- These increases are testosterone-dependent and expected 3
Anastrozole Impact
While anastrozole is mentioned in your clinical scenario, the evidence 4 does not indicate it significantly affects PSA levels. The primary monitoring concern remains testosterone's effect on PSA.
Common Pitfall to Avoid
Do not use screening codes (like Z12.5 for prostate cancer screening) as the primary diagnosis when the patient is on testosterone therapy. The medical necessity stems from monitoring a patient on hormone replacement (E29.1), not routine cancer screening. This distinction is critical for reimbursement and accurately reflects the clinical indication.
Documentation Tips
- Document that PSA testing is for monitoring testosterone therapy per Endocrine Society guidelines
- Note baseline PSA value and any changes from baseline
- Record testosterone dose and formulation
- Include digital rectal examination findings when performed